Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH.
Mol Metab
; 46: 101153, 2021 04.
Article
em En
| MEDLINE
| ID: mdl-33359400
ABSTRACT
BACKGROUND:
Non-alcoholic steatohepatitis (NASH) is a spectrum of histological liver pathologies ranging from hepatocyte fat accumulation, hepatocellular ballooning, lobular inflammation, and pericellular fibrosis. Based on early investigations, it was discovered that visceral fat accumulation, hepatic insulin resistance, and atherogenic dyslipidemia are pathological triggers for NASH progression. As these pathogenic features are common with obesity, type 2 diabetes (T2D), and atherosclerosis, therapies that target dysregulated core metabolic pathways may hold promise for treating NASH, particularly as first-line treatments. SCOPE OF REVIEW In this review, the latest clinical data on nuclear hormone- and peptide hormone-based drug candidates for NASH are reviewed and contextualized, culminating with a discovery research perspective on emerging combinatorial therapeutic approaches that merge nuclear and peptide strategies. MAJORCONCLUSION:
Several drug candidates targeting the metabolic complications of NASH have shown promise in early clinical trials, albeit with unique benefits and challenges, but questions remain regarding their translation to larger and longer clinical trials, as well as their utility in a more diseased patient population. Promising polypharmacological approaches can potentially overcome some of these perceived challenges, as has been suggested in preclinical models, but deeper characterizations are required to fully evaluate these opportunities.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hormônios Peptídicos
/
Hepatopatia Gordurosa não Alcoólica
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article